•  
  •  
  •  
  •  

2026-07-25 05:15:16

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • TANFAC Industries Reports Q1 FY27 Net Profit of ₹16.85 Crore; Operational Revenue Up 6.3% YoY to ₹187.18 Crore
  • New India Assurance Reports Q1 FY27 Net Loss of ₹243.94 Crore; Gross Written Premium Rises 2.9% YoY to ₹13,835 Crore
  • NTPC Consolidated Q1 FY27 Net Profit Rises 12.9% YoY to ₹6,896 Crore; Operational Revenue Up 7.8% at ₹50,741 Crore
  • Neogen Chemicals Reports Q1 FY27 Net Profit Surge of 66.8% YoY to ₹17.11 Crore; Operational Revenue Up 34% at ₹250.29 Crore
  • Arihant Capital Markets Reports Q1 FY27 Net Profit of ₹21.49 Crore, Up 69.2% YoY; Operational Revenue Jumps 53.5%

Keywords Selected:  NDA

Research

  • India Inc revenue growth likely moderated to 4-6% in March quarter - CRISIL Market Intelligence and Analytics

Stock Report

  • Alembic Pharmaceuticals Limited's Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets, 100 mg and 150 mg
  • Uno Minda announces Greenfield Plant in Chhatrapati Sambhaiinagar with Rs. 320 Crore Investment
  • Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dapsone Gel, 5%
  • Lupin receives Tentative Approval from U.S. FDA for Enzalutamide Tablets
  • Concord Biotech Ltd successfully completes PPB and NDA inspection
  • Fire incident at Bathinda Distillery of BCL Industries Limited
  • Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Binimetinib Tablets, 45 mg
  • Concord Biotech Ltd receives ANDA approval for Tofacitinib Tablets, 5 mg and 10 mg
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Haloperidol Tablets, USP, 1 mg, 2 mg, 5 mg, 10 mg, and 20 mg
  • Zydus Therapeutics receives USFDA priority review to NDA for Saroglitazar
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Levothyroxine Sodium Tablets USP
  • Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA
  • Orbicular's Partner secures tentative U.S. ANDA approval for a generic version of Semaglutide Injection, supported by OneSource as CDMO partner
  • Lupin Announces the Approval of Dapagliflozin Tablets in the United States
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Dapagliflozin Tablets, 5 mg and 10 mg
  • Marksans Pharma Ltd receives USFDA approval for Benzonatate Capsules USP, 100 mg & 200 mg (Rx)
  • Alembic Pharmaceuticals Ltd announces USFDA Final Approval for Paroxetine Extended-Release Tablets USP, 12.5 mg
  • Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets
  • Tembo Global Industries' Subsidiary Signs NDA with Defence PSU for Collaboration
  • Vedanta Ltd declared preferred bidder of Karnapodikonda bauxite block
  • Alembic Pharmaceuticals Limited announces USFDA Final Approval for Lamotrigine Orally Disintegrating Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg
  • Caplin Steriles gets USFDA approval for Sodium Phosphates Injection
  • Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL
  • Alembic Pharmaceuticals gets USFDA nod for generic Parkinson's disease treatment tablets

Latest Post

  • TANFAC Industries Reports Q1 FY27 Net Profit of ₹16.85 Crore; Operational Revenue Up 6.3% YoY to ₹187.18 Crore
  • New India Assurance Reports Q1 FY27 Net Loss of ₹243.94 Crore; Gross Written Premium Rises 2.9% YoY to ₹13,835 Crore
  • NTPC Consolidated Q1 FY27 Net Profit Rises 12.9% YoY to ₹6,896 Crore; Operational Revenue Up 7.8% at ₹50,741 Crore
  • Neogen Chemicals Reports Q1 FY27 Net Profit Surge of 66.8% YoY to ₹17.11 Crore; Operational Revenue Up 34% at ₹250.29 Crore
  • Arihant Capital Markets Reports Q1 FY27 Net Profit of ₹21.49 Crore, Up 69.2% YoY; Operational Revenue Jumps 53.5%


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025